EsophagogastroduodenoscopyPhase 4NCT07336680
Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding
A Phase 4 study testing intravenous ondansetron in people with Esophagogastroduodenoscopy and Upper Gastrointestinal Bleeding (UGIB), run by Peking Union Medical College Hospital at 1 site in China.
Trial summary
The goal of this clinical trial is to evaluate whether intravenous ondansetron can improve patient tolerance and reduce discomfort during unsedated emergency esophagogastroduodenoscopy (EGD). Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Esophagogastroduodenoscopy, Upper Gastrointestinal Bleeding (UGIB)
- What is being tested?
- intravenous ondansetron
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteChina
- Study dates
- 16 Feb 2026to 15 Aug 2026
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Presence of suspected or confirmed upper gastrointestinal bleeding with an indication for emergent endoscopic intervention.
- Capability to provide informed consent.
Who cannot join
- Presence of any contraindication to upper gastrointestinal endoscopy.
- Concurrent severe primary diseases of the respiratory, cardio-cerebrovascular, renal, central nervous, or hematologic systems.
- Pregnancy.
- Presence of neuropsychiatric disorders, including severe depression or severe anxiety.
- Presence of a known history of cardiac arrhythmia.
- Allergic to dyclonine hydrochloride or ondansetron.
Trial locations and contacts
1 site in 1 country.
China1 site
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100000
About this study
The goal of this clinical trial is to evaluate whether intravenous ondansetron can improve patient tolerance and reduce discomfort during unsedated emergency esophagogastroduodenoscopy (EGD). The main questions it aims to answer are:
- Does pre-procedural administration of ondansetron improve patient cooperation during emergency EGD?
- Does it improve endoscopic field visibility and improve the success rate of initial endoscopic hemostasis？
- Does it reduce the operator's perceived workload or stress?
Read more
Researchers will compare patients who received intravenous ondansetron with patients who received placebo to see if ondansetron can reduce patient discomfort and improve patient cooperation, therefore improve the quality of the procedure.
Participants will receive either intravenous ondansetron and dyclonine hydrochloride mucilage or intravenous saline and dyclonine hydrochloride mucilage prior to the endoscopic procedure.
- Being tested
- intravenous ondansetron, Placebo
- Medical subject headings
- Gastrointestinal Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
intravenous ondansetronDrug
Intravenous administration of 8 mg ondansetron ( in a 4 mL solution) 0.5-1h prior to endoscopic procedure and gurgle 10 ml dyclonine hydrochloride viscous solution (0.01 g/mL) 15 min prior to the endoscopic procedure.
PlaceboDrug
Intravenous administration of 4 ml saline 0.5-1h prior to endoscopic procedure and gurgle 10 ml dyclonine hydrochloride viscous solution (0.01 g/mL) 15 min prior to the endoscopic procedure.
| Study group | Role | What they receive |
|---|---|---|
| intravenous ondansetron | Experimental | Not described Receives: Drug: intravenous ondansetron |
| control | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
patient cooperation
evaluated by the endoscopist in numeric rating scale, 0 stands for not good at all, 10 stands for completely satisfied.
Measured: from the beginning to the end of the endoscopic procedure
Secondary outcomes (9)
gagging intensity of patient
gagging intensity of patient evaluated by the endoscopist, in numeric rating scale, 0 means none, 10 means extremely intense.
Measured: from the beginning to the end of the endoscopic procedure
endoscopist workload
Self-assessed by the endoscopist immediately after the procedure. It is measured via the NASA task load index (NASA-TLX) across six dimensions-mental demand, physical demand, temporal demand, effort, performance, and frustration. A 0-100 mm visual analogue scale is for each dimension, where 0 represents "very low" and 100 represents "very high".
Measured: From the beginning to the end of the endoscopic procedure
visualization quality
Overall endoscopic visualization was evaluated at 4 locations including (i) gastric fundus, (ii) corpus, (iii) antrum, and (iv) duodenal bulb. The score is rated in the following criteria: 0, less than 25% of the surface was visible; 1, 25%-75% visible; and 2, more than 75% visible. The total score range was 0-8.
Measured: During the endoscopic procedure.
Success rate of initial endoscopic hemostasis
the proportion of patients in each group who achieved hemostasis with a single endoscopic intervention
Measured: from the beginning to the end of the endoscopic procedure
Proportion of patients needing repeat endoscopy within 72 hours
The proportion of patients who underwent a repeat upper gastrointestinal endoscopy for suspected rebleeding within 72 hours following the completion of the initial endoscopic procedure.
Measured: from the time of the endoscopic procedure to 3 days after the endoscopic procedure.
Recurrence of UGIB in 7 days
The proportion of patients in whom hemostasis was initially achieved by endoscopy, but who subsequently experienced recurrent bleeding within 7 days. Recurrent bleeding is defined by the occurrence of any of the following: hematemesis, melena, hematochezia, hemodynamic instability, or endoscopic confirmation of recurrent bleeding at the original site.
Measured: from the day of the procedure to 7 days after it
Recurrence of UGIB in 30 days
The proportion of patients in whom hemostasis was initially achieved by endoscopy, but who subsequently experienced recurrent bleeding within 30 days. Recurrent bleeding is defined by the occurrence of any of the following: hematemesis, melena, hematochezia, hemodynamic instability, or endoscopic confirmation of recurrent bleeding at the original site.
Measured: From the day of the procedure to 30 days after it
adverse event
Any adverse medical event occurring during the endoscopic procedure, regardless of its relationship to the study medication.
Measured: from the beginning of the intervention to the end of the endoscopic procedure
Procedure duration
Measured: From the start to the end of the endoscopic procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study start16 Feb 2026
- Primary completion15 Jul 2026
- Study completion15 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EsophagogastroduodenoscopyStudies of the same condition, open and under way.
- More trials run by Peking Union Medical College HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Peking Union Medical College Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, DONG WU, Peking Union Medical College Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07336680
- Sponsor's protocol ID
- ON-UGIB25
- Status last verified
- Sep 2026
- First submitted
- 2 Jan 2026
- Last updated
- 16 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding
- ClinicalTrials.gov ID
- NCT07336680
- Acronym / sponsor ID
- ON-UGIB25
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Peking Union Medical College HospitalUniversity, hospital or other
- Study start
- 16 Feb 2026 (actual)
- Primary completion
- 15 Jul 2026 (actual)
- Study completion
- 15 Aug 2026 (actual)
- First posted
- 13 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate whether intravenous ondansetron can improve patient tolerance and reduce discomfort during unsedated emergency esophagogastroduodenoscopy (EGD). The main questions it aims to answer are:
- Does pre-procedural administration of ondansetron improve patient cooperation during emergency EGD?
- Does it improve endoscopic field visibility and improve the success rate of initial endoscopic hemostasis？
- Does it reduce the operator's perceived workload or stress?
Researchers will compare patients who received intravenous ondansetron with patients who received placebo to see if ondansetron can reduce patient discomfort and improve patient cooperation, therefore improve the quality of the procedure.
Participants will receive either intravenous ondansetron and dyclonine hydrochloride mucilage or intravenous saline and dyclonine hydrochloride mucilage prior to the endoscopic procedure.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| intravenous ondansetron | Experimental | Drug: intravenous ondansetron |
| control | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Presence of suspected or confirmed upper gastrointestinal bleeding with an indication for emergent endoscopic intervention.
- Capability to provide informed consent.
Key exclusion criteria (6 listed)
- Presence of any contraindication to upper gastrointestinal endoscopy.
- Concurrent severe primary diseases of the respiratory, cardio-cerebrovascular, renal, central nervous, or hematologic systems.
- Pregnancy.
- Presence of neuropsychiatric disorders, including severe depression or severe anxiety.
- Presence of a known history of cardiac arrhythmia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| intravenous ondansetronIntravenous administration of 8 mg ondansetron ( in a 4 mL solution) 0.5-1h prior to endoscopic procedure and gurgle 10 ml dyclonine hydrochloride viscous solution (0.01 g/mL) 15 min prior to the endoscopic procedure. | Drug | intravenous ondansetron |
| PlaceboIntravenous administration of 4 ml saline 0.5-1h prior to endoscopic procedure and gurgle 10 ml dyclonine hydrochloride viscous solution (0.01 g/mL) 15 min prior to the endoscopic procedure. | Drug | control |
Primary outcome
patient cooperation
Time frame: from the beginning to the end of the endoscopic procedure
evaluated by the endoscopist in numeric rating scale, 0 stands for not good at all, 10 stands for completely satisfied.
9 secondary outcomes
gagging intensity of patient
Time frame: from the beginning to the end of the endoscopic procedure
endoscopist workload
Time frame: From the beginning to the end of the endoscopic procedure
visualization quality
Time frame: During the endoscopic procedure.
Success rate of initial endoscopic hemostasis
Time frame: from the beginning to the end of the endoscopic procedure
Proportion of patients needing repeat endoscopy within 72 hours
Time frame: from the time of the endoscopic procedure to 3 days after the endoscopic procedure.
Recurrence of UGIB in 7 days
Time frame: from the day of the procedure to 7 days after it
Recurrence of UGIB in 30 days
Time frame: From the day of the procedure to 30 days after it
adverse event
Time frame: from the beginning of the intervention to the end of the endoscopic procedure
Procedure duration
Time frame: From the start to the end of the endoscopic procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2026.
Related trials for Esophagogastroduodenoscopy
Not yet recruitingObservational study
Media Use, Anxiety, Sedation, and Recovery in Children Having Upper GI Endoscopy
Anesthesia, Anxiety
Not yet recruiting
Gastric Emptying After a Yoghurt Breakfast in Children: a Pilot Study
Preoperative Fasting
RecruitingObservational study
ENDoscopic Assessment in Acute PANcreatitis Study (ENDOPAN Study)
Acute Pancreatitis (AP)
Active, not recruiting
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
Barrett Esophagus, Esophageal Adenocarcinoma
RecruitingPhase 3
Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.
GLP-1
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing intravenous ondansetron in people with Esophagogastroduodenoscopy and Upper Gastrointestinal Bleeding (UGIB), run by Peking Union Medical College Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
patient cooperation (time frame: from the beginning to the end of the endoscopic procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.